Niraparib / Abirateronacetat (2) – Akeega®

Name: Frühe Nutzenbewertungen nach § 35a SGB V
Creator: Gemeinsamer Bundesausschuss

Metastatic, hormone-sensitive prostate cancer; BRCA1/2 mutations; combination with prednis(ol)one and androgen deprivation therapy

Start date	15.03.2026
Resolution	03.09.2026 – active procedure
INN	Niraparib/Abirateronacetat
Brand name	Akeega®
Pharm. company	Janssen-Cilag GmbH
G-BA Procedure ID	D-1314
Therapeutic area	Oncological diseases
Reason for procedure	New therapeutic indication

active procedures repealed resolutions


15.03.2026	03.09.2026	Niraparib / Abirateronacetat (2)	Akeega®	Janssen-Cilag GmbH	Oncological diseases	Metastatic, hormone-sensitive prostate cancer; BRCA1/2 mutations; combination with prednis(ol)one and androgen deprivation therapy	n.d.	active procedure
15.11.2023	02.05.2024	Niraparib / Abirateronacetat (1)	Akeega®	Janssen-Cilag GmbH	Oncological diseases	Prostate carcinoma, metastastic, castration resistent, BRCA1/2-Mutation, Chemotherapy not indicated, combination with prednis(ol)one	1,030–2,200	50% Hint for considerable additional benefit

<< List of all resolutions